Simulations Plus, Inc. (SLP: Quote), a provider of simulation software for pharmaceutical development, said Monday that it expects revenues of $2.8 million for the second quarter of fiscal 2012, up 6.4 percent from last year's revenue of $2.6 million.
The company said that approximately 15 percent of the revenues came from new software licenses and 4 percent from consulting studies.
Walt Woltosz, chief executive officer of Simulations Plus, said, "Fiscal year 2012 continues our trend of growth and profitability with a new record for any quarter in our second quarter, layering on top of our announced record first quarter revenue. We are focused on increasing our market penetration and delivering accelerating operating leverage as incremental top-line growth drives faster bottom-line increases."
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org